Download presentation
Presentation is loading. Please wait.
1
Parkinson Disease Psychosis
2
This program may include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
3
PD and PDP: Overview
4
Recognizing PDP
5
Recognizing PDP (cont)
6
Hallucinations and Delusions: Hallmarks of PDP
7
Are You Seeing Things? Queries for the Patient
8
Steps Before Prescribing an Antipsychotic Patient Assessment
9
Considerations When Prescribing an Antipsychotic
10
Pimavanserin: 5-HT2A Inverse Agonist
11
Improving Collaborative Care
12
Medications Used for PDP
13
FDA Pimavanserin Analysis No New or Unexpected Risks
14
Challenges of PDP Care
15
Monitoring Pimavanserin Use
16
Concluding Remarks
17
Abbreviations
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.